Effectiveness of add‐on therapy with SGLT2 inhibitors or GLP ‐1 receptor agonists in adults with type 1 diabetes: A prospective DPV registry study

Documenti analoghi

• Analysis of patient characteristics and safety of insulin glargine U300 use in 21 359 patients with type‐2 diabetes and chronic kidney disease: DPV registry study
  di: Anjaly Vijayan, et al.
  Pubblicazione: (2025)
• Adherence to GLP ‐1 receptor agonists and SGLT2 inhibitors by out‐of‐pocket spending among Medicare beneficiaries with diabetes
  di: Nicklas S. Klepser, et al.
  Pubblicazione: (2025)
• Efficacy and safety of GLP ‐1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta‐analysis
  di: Sama M. Abdel‐Rahman, et al.
  Pubblicazione: (2026)
• Increased cardiovascular risk in people with LADA in comparison to type 1 diabetes and type 2 diabetes: Findings from the DPV registry in Germany and Austria
  di: Rosa C. Golomb, et al.
  Pubblicazione: (2024)
• The importance of treatment sequencing with SGLT2 inhibitors and GLP ‐1 receptor agonists combination for kidney function preservation in type 2 diabetes
  di: Mario Luca Morieri, et al.
  Pubblicazione: (2026)